Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 11, 2008

Alnylam and Max Planck Institute Ally to Investigate Uptake of RNAi Drugs

  • Alnylam Pharmaceuticals and Max Planck Institute of Molecular Cell Biology and Genetics are working together to understand the molecular mechanisms behind intracellular transport of siRNA.

    Under the exclusive research agreement, Alnylam scientists will work closely with the laboratory of Marino Zerial, Ph.D., to investigate cellular uptake pathways in a high-throughput manner. Alnylam will have an option on any resulting intellectual property.

    “Through this collaboration,” notes Marino Zerial, Ph.D., research group leader and director at the Max Planck Institute of Molecular Cell Biology and Genetics, “we will increase our understanding of how different siRNA formulations are internalized within cells and then use this knowledge to further optimize approaches for delivery of RNAi therapeutics.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »